



Contacts: Meg McGilley
Chief Financial Officer
(858) 480-0402

Rob Whetstone
PondelWilkinson Inc.
(310) 279-5963

Somaxon Pharmaceuticals to Report 2008 First Quarter Results and Host Conference Call on May 6, 2008

SAN DIEGO, CA – April 29, 2008 – Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) today announced that it will release its 2008 first quarter financial results after the market closes on Tuesday May 6, 2008. Somaxon management will host a conference call that same afternoon at 4:30 p.m. ET (1:30 p.m. PT) to review the financial results and answer questions.

The conference call will be available to interested parties through a live audio Internet broadcast at <http://investors.somaxon.com/events.cfm>. The call will also be archived and accessible for fourteen days. Alternatively, callers may participate in the conference call by dialing (800) 240-4186 (domestic) or (303) 262-2143 (international). A telephonic replay will be available for approximately one week following the conclusion of the call by dialing (800) 405-2236 (domestic) or (303) 590-3000 (international), and entering passcode 11113678.

About Somaxon Pharmaceuticals, Inc.

Headquartered in San Diego, CA, Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the in-licensing and development of proprietary product candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology. Somaxon has completed four successful Phase 3 clinical trials for its lead product candidate, SILENOR™ (doxepin HCl) for the treatment of insomnia. The U.S. Food and Drug Administration (FDA) recently notified Somaxon that it accepted the New Drug Application (NDA) for SILENOR™ for review as of March 31, 2008. Pursuant to Prescription Drug User Fee Act (PDUFA) guidelines, Somaxon expects that the FDA will complete its review and provide an action letter to the company with respect to the NDA by December 1, 2008.

For more information, please visit the company's web site at www.somaxon.com.

###